Search

Memorial Sloan Kettering Cancer Center (MSK) is partnering with PathPresenter, a leader in digital pathology workflow software, to integrate DeepLIIF, MSK’s new artificial intelligence (AI) algorithm, into PathPresenter’s image management platform for oncology research.

… Monday, April 14, 2025 Memorial Sloan Kettering Cancer Center (MSK) is partnering with PathPresenter, a leader in digital pathology workflow software, to integrate DeepLIIF, MSK’s new artificial intelligence (AI) algorithm, into PathPresenter’s image management platform for oncology research. DeepLIIF

… Thursday, October 6, 2022 Perry Ortiz doesn’t remember having a seizure in 2016. Or being rushed to an operating room, where doctors confirmed Perry — a security supervisor at Memorial Sloan Kettering Cancer Center (MSK) — had stage 2 testicular cancer . His only recollection of that day six years ago

The US Food and Drug Administration has updated its recommendations for the use of Gardasil 9, the vaccine that protects against human papillomavirus (HPV), to include people age 27 to 45. Previously, Gardasil 9 was only approved for use in those between age nine and 26. 

… Thursday, October 18, 2018 The US Food and Drug Administration has updated its recommendations for the use of Gardasil 9, the vaccine that protects against human papillomavirus (HPV), to include people age 27 to 45. Previously, Gardasil 9 was only approved for use in those between age nine and 26.  This

Read about a new discovery that could lead to more powerful cell-based therapies for cancer.

… Tuesday, July 22, 2025 A team of Memorial Sloan Kettering Cancer Center (MSK) researchers have made an important finding about why genetically engineered immune cells sometimes fail to finish the job when given as a cancer treatment. The new discovery sheds light on the tendency of these modified cells

The success of science, research, and medicine in saving and extending lives requires the transfer of ideas and knowledge in the laboratory, classroom, hospitals and clinics. The Executive Order issued on June 22 that suspends the issuing of temporary visas for certain foreign workers will only impede the innovation and scientific leadership that the world has come to expect from the United States.

… Wednesday, June 24, 2020 The success of science, research, and medicine in saving and extending lives requires the transfer of ideas and knowledge in the laboratory, classroom, hospitals and clinics. Shutting off access to the brightest and most talented scientists and clinicians from around the world

Karen Granville works as a patient advocate to increase their access to MSK for cancer treatment.

… Tuesday, March 8, 2022 An Advocate for Patients with Cancer As a registered nurse for the past 13 years, Karen Granville , who now serves as a Nurse Case Manager for Patient Financial Services at MSK, empathizes with the struggles faced by our patients with cancer. “It’s easy to lose hope,” Ms. Granville

Norwalk Hospital and Memorial Sloan Kettering Cancer Center (MSK) today announced MSK Physicians at Norwalk Hospital, a new cancer care collaboration that will integrate MSK medical and radiation oncologists and care practices with the existing cancer program at the C. Anthony and Jean Whittingham Cancer Center at Norwalk Hospital.

… Monday, October 16, 2017 Norwalk Hospital and Memorial Sloan Kettering Cancer Center (MSK) today announced MSK Physicians at Norwalk Hospital , a new cancer care collaboration that will integrate MSK medical and radiation oncologists and care practices with the existing cancer program at the C. Anthony

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Michel Sadelain, MD, PhD, renowned physician-scientist, Director of the Center for Cell Engineering, and Stephen and Barbara Friedman Chair, has been awarded the 2024 Breakthrough Prize in Life Sciences.

… Thursday, September 14, 2023 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Michel Sadelain, MD, PhD, renowned physician-scientist, Director of the Center for Cell Engineering, and Stephen and Barbara Friedman Chair, has been awarded the 2024  Breakthrough Prize in Life Sciences

Bevacizumab (Avastin®) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III "OCEANS" trial were presented today by the lead author, Carol Aghajanian, MD, of Memorial Sloan Kettering Cancer Center, at the 2011 annual meeting of the American Society of Clinical Oncology.

… Saturday, June 4, 2011 Bevacizumab (Avastin®) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer , according to a new study. Results from the phase III “OCEANS” trial were presented today by the lead author, Carol Aghajanian, MD , of Memorial Sloan

The FDA has approved an engineered cell therapy called afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for treating advanced synovial sarcoma. The clinical trials resulting in the drug’s approval were led by Dr. Sandra D’Angelo of MSK.

… Friday, August 2, 2024 The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleucel (Tecelra ® , also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called  synovial sarcoma . Afami-cel is the first engineered